10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Desiccated,Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 ( LPA1 ) antagonist BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC 50 s of 4.8 µM, 6.2 µM, and 7.5 µM for BSEP, MRP4, and MDR3, respectively BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF)
In Vitro
BMS-986020 sodium (0.1-10 nM; pre-incubated) concentration-dependent displacement of [ 18 F]BMT-083133 binding is observed in LPA1 + cells and lung sections. At 0.1 nM, the percent displacement in healthy mice, bleomycin mice, and IPF lungs is 18%, 24%, and 31%, respectively. At 10 nM, the percent displacement is 73%, 76%, and 64%, respectively. [ 18 F]BMT-083133, a radioligand targeting LPA1 is developed as a translational research tool for assessment of lung LPA1 engagement of BMS-986020 using in vitro autoradiography (ARG) . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
IC50& Target:IC50: 4.8 µM (BSEP),6.2 µM (MRP4),7.5 µM (MDR3)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →